Reviewing Evaxion A/S (NASDAQ:EVAX) and Hims & Hers Health (NYSE:HIMS)

Evaxion A/S (NASDAQ:EVAX) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.

Earnings & Valuation

This table compares Evaxion A/S and Hims & Hers Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53 million	4.97	-$7.71 million	($1.32)	-3.40
Hims & Hers Health	$2.35 billion	2.66	$128.37 million	$0.51	53.65

Hims & Hers Health has higher revenue and earnings than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Evaxion A/S and Hims & Hers Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1	0	5	0	2.67
Hims & Hers Health	1	13	4	0	2.17

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 144.99%. Hims & Hers Health has a consensus price target of $32.53, suggesting a potential upside of 18.90%. Given Evaxion A/S’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Evaxion A/S is more favorable than Hims & Hers Health.

Institutional & Insider Ownership

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Comparatively, 13.7% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Evaxion A/S has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

Profitability

This table compares Evaxion A/S and Hims & Hers Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-29.14%
Hims & Hers Health	5.47%	22.48%	7.02%

Summary

Hims & Hers Health beats Evaxion A/S on 9 of the 14 factors compared between the two stocks.

About Evaxion A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.